AN AUDIENCE WITH 13 September 2024

Najat Khan — Chief R&D Officer and Chief Commercial Officer at Recursion — discusses the proposed merger of Recursion and Exscientia.

When Recursion launched in 2013, the fledgling biotech’s goal was to turn machine vision loose on images of cells, at scale, to better understand the biology of disease. Exscientia, founded the year before, set out by contrast to code algorithms that would enable medicinal chemists to better explore chemical space. Over the past decade, both firms have leaned into expectations that these and related computational approaches will make drug discovery better, faster and cheaper. The two companies now want to become one, betting that an AI-first, ‘full-stack’ small-molecule discovery engine can deliver the drug discovery goods.

Access options

Access Nature and 54 other Nature Portfolio journals

Get Nature+, our best-value online-access subscription

24,99 € / 30 days

cancel any time

Subscription info for Chinese customers

We have a dedicated website for our Chinese customers. Please go to naturechina.com to subscribe to this journal.

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

doi: https://doi.org/10.1038/d41573-024-00149-6

Interviewed by Asher Mullard

Questions and answers have been edited for length and clarity.

Jobs